OKYO Pharma Limited
NASDAQ:OKYOBiotechnology
+$0.01 today
- Market cap
- $57.73M
- Beta
- 0.02
- P/E (TTM)
- -12.8
- EPS (TTM)
- -$0.12
Volume 0.24M
Average 0.07M
OKYO Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Gross Margin history
Percent of revenue · from the income statement
No Gross Margin data reported for this period type.
Gross Margin vs competitors
How OKYO compares with its peers on the latest reported figures
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 100.0% | +20.1 pp | +326.6 pp | |
| LTM Mar 2026 | 99.8% | +378.1 pp | — | |
WHWKWhitehawk Therapeutics Inc | FY2025 | 89.4% | +197.4 pp | +212.8 pp |
| LTM Mar 2026 | 69.9% | +7.9 pp | -24.0 pp | |
| LTM Mar 2026 | -182.1% | -260.9 pp | -16.0 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding OKYO) | 89.4% | +20.1 pp | +98.4 pp | |
Competitors are the stored peer set for OKYO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Mar 2021 | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 13.09K | 2.42K | 3.8K | 3.87K | 2.56K |
| Gross Profit | (13.09K) | (2.42K) | (3.8K) | (3.87K) | (2.56K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 348.35K | 1.61M | 6.34M | 8.24M | 2.25M |
| Selling, General & Admin | 2.97M | 4.93M | 6.75M | 7.45M | 4.93M |
| Operating Expenses | 3.37M | 6.22M | 6.34M | 15.69M | 7.19M |
| Depreciation & Amortization | 13.11K | 2.33K | 3.8K | 3.87K | 2.56K |
| EBITDA | (3.35M) | (6.22M) | (13.18M) | (15.75M) | (7.08M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (4.13M) | (6.23M) | (13.09M) | (15.69M) | (7.19M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 0 | 5.47K |
| Interest Expense | 1.12K | 0 | 96.69K | 1.05M | 883.65K |
| Other Income / Expenses | 754.85K | 13.58K | (196.62K) | (1.11M) | (781.2K) |
| Income Before Tax | (3.38M) | (6.22M) | (13.28M) | (16.8M) | (7.97M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (24.99K) | (787K) | (12.2K) | 22.42K | (3.26M) |
| Net Income | (3.35M) | (5.43M) | (13.27M) | (16.83M) | (4.71M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.32) | (0.36) | (0.60) | (0.00) | (0.12) |
| EPS (Diluted) | (0.32) | (0.36) | (0.60) | (0.00) | (0.12) |
| Weighted Avg Shares | 10.35M | 15.06M | 22.26M | 29.34M | 39.49M |
| Weighted Avg Shares (Diluted) | 10.35M | 15.06M | 22.26M | 29.34M | 39.49M |
OKYO Pharma Limited
NASDAQ:OKYO
Intrinsic Alpha fair value
Locked
Current Price
$1.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.